Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

INNOCARE
诺诚健华

InnoCare Pharma Limited
諾誠健華醫藥有限公司
(Incorporated in the Cayman Islands with limited liability)
(Stock code: 9969)

VOLUNTARY ANNOUNCEMENT

APPROVAL OF ORELABRUTINIB FOR THE FIRST-LINE TREATMENT OF CLL/SLL IN CHINA

This announcement is made by InnoCare Pharma Limited (the "**Company**") on a voluntary basis to inform the shareholders and potential investors of the Company about the latest business advancement of the Company.

The board of directors of the Company (the "**Board**") is pleased to announce that our core product 宜諾凱® (Orelabrutinib, Bruton Tyrosine Kinase ("**BTK**") inhibitor) received approval from the China National Medical Products Administration (NMPA) for the first-line treatment of patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). Meanwhile, orelabrutinib has also been listed as a Class I recommended therapy for the first-line treatment of CLL/SLL in the Chinese Society of Clinical Oncology (CSCO) Lymphoma Diagnosis and Treatment Guidelines 2025.

Previously orelabrutinib has been approved for the treatment of three indications in China, including relapsed and refractory CLL/SLL, relapsed and refractory mantle cell lymphoma (r/r MCL) and relapsed and refractory marginal zone lymphoma (r/r MZL), all of which have been covered in the National Reimbursement Drug List. The approval of the first-line CLL/SLL treatment will enable orelabrutinib to benefit an even broader population of lymphoma patients.

Cautionary Statement as required by Rule 18A.08(3) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited: There is no assurance that the Company will ultimately commercialize orelabrutinib for the first-line treatment of CLL/SLL successfully. Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By Order of the Board
InnoCare Pharma Limited
Dr. Jisong Cui
Chairperson and executive Director

Hong Kong, 25 April 2025

As at the date of this announcement, the Board of Directors comprises Dr. Jisong Cui as Chairperson and executive Director, Dr. Renbin Zhao as executive Director, Dr. Yigong Shi and Mr. Ronggang Xie as non-executive Directors, and Ms. Lan Hu, Dr. Dandan Dong and Prof. Kunliang Guan as independent non-executive Directors.